On December 6, 2023 Ten63 Therapeutics, a biotechnology company unlocking previously undruggable targets by leveraging proprietary algorithms combining interpretable generative AI and physics-based models, reported a multi-target drug discovery collaboration with Boehringer Ingelheim (Press release, Ten63 Therapeutics, DEC 6, 2023, View Source [SID1234638198]). The new partnership is aiming to enable the discovery of novel therapeutic molecules, to address diseases that are out of reach of conventional drug discovery, i.e. diseases with high unmet patient needs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Hundreds of millions of people are living with diseases that to date cannot be cured or are inadequately treated and which limit the daily activities or life expectancy of affected individuals. New technologies are needed to accelerate the discovery of medicines addressing molecular targets, which have so far eluded attempts to create effective treatment approaches.
The collaboration will apply Ten63’s computational drug discovery engine, BEYOND, to discover novel molecules for multiple Boehringer Ingelheim targets in diverse indications, and leverage Boehringer Ingelheim’s expertise in pre-clinical discovery and drug development.
Ten63’s CEO Dr. Marcel Frenkel said: "Ten63 is proud to partner with Boehringer Ingelheim on finding new molecules addressing challenging Boehringer targets that could have a tremendous impact on human lives. We believe the combination of Ten63’s BEYOND platform with Boehringer’s leading discovery and development capabilities will be a powerful combination to bring groundbreaking therapeutics to patients."
The BEYOND platform is composed of a suite of proprietary algorithms designed to enable drug discovery for targets that are difficult for conventional drug discovery technologies. BEYOND combines cryptic pocket discovery with a data-independent and interpretable generative chemistry engine to find potent drug candidates by completely exploring the conformational and chemical space of over 100 trillion synthetically feasible drug-like molecules to provably find the best solutions given Ten63’s state-of-the-art models. Furthermore, BEYOND learns from every iteration of chemistry, combining target specific data generated by the platform with models based on large external data sets to quickly allow it to transfer prediction of multiple absorption, distribution, metabolism and excretion (ADME) properties accurately to new chemical space.
Financial terms of the collaboration are not disclosed.